Navigation Links
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy

SAN FRANCISCO, Nov. 8 /PRNewswire/ -- Jennerex, Inc. today announced the addition of Mr. Robert A. Ingram as Special Advisor to the Chairman and to The President & CEO, and the hiring of Mr. Marty Glick as Executive Vice President, Corporate Strategy.

Bob Ingram is Vice Chairman, Pharmaceuticals at GlaxoSmithKline (plc), and previously served as Chief Executive Officer, Chief Operating Officer and President of Pharmaceutical operations for Glaxo Wellcome. Mr. Ingram is Chairman of the Board of Directors of OSI Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, and a member of the Board of Directors of Allergan, Inc., Lowe's Companies, Edwards Lifesciences Corporation, and Wachovia Corporation.

"We are delighted to welcome Bob to the Jennerex team. His experience in leading companies which have successfully developed and commercialized major new medicines adds significant strategic depth to our team," said Brennan Mulcahy, Chairman of Jennerex.

"I am excited to work with the Board and CEO of Jennerex to develop and commercialize a new class of biotherapeutics for the treatment of several major types of cancer," said Bob Ingram.

"We know Bob's extensive pharmaceutical leadership experience will be invaluable to Jennerex as we leverage our innovative technology platform to develop and commercialize major new medicines to treat patients with serious unmet needs in oncology, including liver cancer, melanoma and lung cancer," said David H. Kirn, M.D., President and Chief Executive Officer.

Mr. Glick was Executive Vice President and Chief Financial Officer of Theravance, Inc. until 2005. He led the efforts to successfully raise over $350 million of private and public equity and to form an innovative strategic alliance with GlaxoSmithKline. Prior to Theravance, Mr. Glick held the position of Vice President Finance at Genentech Inc where he was involved in structuring major deals such as in-licensing of Rituxan(R) from Idec (now Biogen Idec). Marty was also a co-founder and Board member of Eyetech Pharmaceuticals.

"Marty's experience in working with top management to successfully finance and build emerging biopharmaceutical companies is an important addition to our team as we drive our lead product candidate toward late stage clinical development and commercialization," said Dr. Kirn.

About Jennerex

Jennerex Biotherapeutics is a clinical stage biotherapeutics company working to create, develop and commercialize first-in-class cancer products. Our products are engineered viruses that have been modified to be safe and effective against various forms of cancer. Jennerex products kill cancer by targeting, attacking and eradicating cancer cells. Our lead product candidate, JX-594, has demonstrated clear anti-cancer effects in a Phase 1 study in patients with late-stage liver cancer. Jennerex has initiated a Phase 2a clinical trial in the U.S., for liver cancer and is currently enrolling a Phase 2a clinical trial at several sites in the U.S. for metastatic melanoma. Jennerex is also planning a Phase 1 study with IV administration focusing on lung cancer and melanoma.

For more information about Jennerex, please visit

SOURCE Jennerex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
(Date:11/24/2015)... 24, 2015 HemoShear Therapeutics, LLC, a ... for metabolic disorders, announced today the appointment of ... of Directors (BOD). Mr. Watkins is the former ... Sciences (HGS), and also served as the chairman ... Powers , Chairman and CEO of HemoShear Therapeutics. ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):